hepatitis b vaccination: an alternative (re)view geert leroux-roels center for vaccinology ghent...
TRANSCRIPT
![Page 1: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/1.jpg)
Hepatitis B vaccination:an alternative (re)view
Geert Leroux-RoelsCenter for Vaccinology
Ghent University and Hospital
![Page 2: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/2.jpg)
Overview of the presentation
• the virus• the infection• the immune response• the HBV vaccine: HBsAg• non-response to HBsAg• strategies to overcome non-
response• immune memory
![Page 3: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/3.jpg)
![Page 4: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/4.jpg)
HBV genome organization
![Page 5: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/5.jpg)
(
(
(
ccc-DNA
RNA
Precore, L, M, S + Xproteins
Capsidprotein
P proteinReverse transcription
ER/IC
Golgi
The HBV infectious cycle
RNA pregenome
cap
![Page 6: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/6.jpg)
Viral clearance without destruction of infected cells during acute HBV infectionLuca Guidotti et al. Science 284:825- 829, 1999
Infectious serum containing ~ 5x107 genome equivalents of HBV (ayw) from transgenic mice2 healthy chimps developed typicalacute,self-limited HBV infectionsdocumented with
- serological- virological- histopathological- molecular
analyses on serum specimens and liver biopsies that were obtained
weekly
![Page 7: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/7.jpg)
HBeAg
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
HBsAg
-HBs
-HBe
-HBc
SerumHBV-DNA
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
sALT
%HBcAg+ hepatocytes
CD3CD8
CD4
Based on Guidotti et al. Science 284:825, 1999
![Page 8: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/8.jpg)
The adaptive immune response to HBV
CD4+Th cell
CD8+
CTLHepatocyte
TNF-IFN-
Lysis
IFN-
APC
YY
B cellY
Th2>Th1cytokines
-HBe
-HBc -HBs
![Page 9: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/9.jpg)
The Hepatitis B vaccine : choice of the immunogen
• A 1 minute boil of MS2 serum (HBV) destroyed infectivity, but left immunogenicity
• HBsAg is an envelope protein• recovery of acute HBV infection is
characterized by HBsAg/anti-HBs seroconversion
• passively acquired anti-HBs protects individuals from infection with HBV
![Page 10: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/10.jpg)
Envelope proteins
of HBV and HBV vaccines
![Page 11: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/11.jpg)
HBsAg vaccine is effective in preventing HBV infection despite the fact that :
• Anti-HBs is not strictly a ‘neutralizing’ antibody, since HBsAg is probably not the receptor-binding element of HBV
• HBsAg is a poor immunogen
• HBsAg has anti-inflammatory qualities
![Page 12: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/12.jpg)
HBV - Hepatocyte interactions (1)
HBV
• preS1
• preS2
Hepatocyte
• Glyceraldehyde-3-P dehydrogenase • IgA receptor• Interleukin 6 • Asialoglycoprotein receptor
• Transferrin receptor• Polymerized-albumin-receptor• Fibronectin
![Page 13: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/13.jpg)
HBV - Hepatocyte interactions (2)
HBV
• HBsAg
Hepatocyte
• Annexin V• Apolipoprotein H• CD14
Lipids play an important role in these interactionsNeurath et al. Virology 1994;204:475Vanlandschoot et al. unpublished
![Page 14: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/14.jpg)
Molecular structure of the major hydrophilic region of HBsAg
K 122d/y
a
![Page 15: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/15.jpg)
Mechanisms of action of anti-HBs ?
Liver
Y
Y
Y
YRapid clearance
of infection
Improve antigen presentation
Improve T cell response
Y
m T
Prevent cell entry
HBV
Anti-HBs
Uptake via FcR
![Page 16: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/16.jpg)
HBsAg is a poor immunogenAnti-HBs
VAX 1 VAX2 VAX 3 VAX4 VAX5Subject Day 0 W2 W4 W6 W8 W16 W18 W20
16 <1 <1 <1 <1 <1 <1 <1 217 <1 <1 <1 <1 <1 10 33 30018 <1 <1 <1 <1 <1 <1 <1 <119 <1 <1 <1 <1 <1 <1 <1 120 <1 <1 3 6 5 16 850 142021 2 <1 2 4 8 36 132 125022 <1 <1 <1 <1 <1 <1 <1 <123 <1 <1 <1 <1 <1 <1 <1 <124 <1 <1 <1 <1 <1 <1 117 141025 <1 <1 <1 <1 <1 2 7 2826 <1 <1 <1 <1 <1 <1 8 1427 <1 <1 <1 <1 <1 <1 4 10228 <1 <1 <1 <1 <1 <1 <1 729 <1 <1 <1 <1 <1 11 28 5830 <1 <1 <1 <1 <1 2 7 66
VAX = 20 µg SL* in PBS
![Page 17: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/17.jpg)
HBsAg is ‘special’
• Produced by HBV-infected hepatocytes• Circulates in serum of chronic HBV
patients at 50-300 µg/ml• HBsAg contains 30% lipids• HBsAg binds to CD14 expressing cells
– monocytes, macrophages– suppresses inflammatory responses
![Page 18: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/18.jpg)
CD
14C
D19
CD
3IS
O
FSC SA-PE b-rHBsAg+
SA-PE
Cell
CD14CD14
CD14
B
B
BB
B
SA-PE
Interaction between HBsAgand CD14+ cells
![Page 19: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/19.jpg)
HBsAg binds to monocytes andsuppresses their activation by
LPS
LPS
HBsAg
TNF, IL1, ..-
LBP
Monocyte/m
![Page 20: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/20.jpg)
Host factors determining response to HB vaccines
• Gender
• Age
• Concomitant illness
• Genetic factor - MHC
![Page 21: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/21.jpg)
Influence of H-2 genotype on the humoral immune response to
HBsAg particles of different compositions
Immunogen Strain H-2 Specific antibody titer (1/dilution)
S PreS2 PreS1
HBsAg (S) B10.D2B10.SB10.M
dsf
81,92000
000
000
+ S B10.D2
B10.M
d
f
40,960
0
10,240
0
0PreS2B10.S s 1,280 10,240 0
0
PreS1 +PreS2+ S
B10.D2B10.SB10.M
dsf
81,9205,12010,240
5,12010,2401,280
6401,280
10,240
Milich et al. J. Immunol. 1986;137:315
![Page 22: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/22.jpg)
Response to HB vaccine:
multiple HLA genes are involved GOOD RESPONSE
is associated with
DRB1*010-
DR5
DPB1*040-
DQB1*0301
DQB1*0501
NON/POOR RESPONSE
is associated with
DRB1*07
DPB1*1101
DQB1*020-
Desombere et al. Tissue Antigens 1998;51:593-604
![Page 23: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/23.jpg)
Antibody production requires cooperationbetween macrophages, T cells and B cells
HLADP, DQ, DR
TCR
Peptide fragmentof antigen
Non-response resides at the level of APC-TCR interaction
![Page 24: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/24.jpg)
Strategies to overcome nonresponsiveness
• Add preS-epitopes to HBsAg vaccine
• Change vaccine carrier– DNA vaccines– HBcAg as carrier
• More immunogenic adjuvants
• Give additional vaccine doses
![Page 25: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/25.jpg)
Influence of H-2 genotype on the humoral immune response to
HBsAg particles of different compositions
Immunogen Strain H-2 Specific antibody titer (1/dilution)
S PreS2 PreS1
HBsAg (S) B10.D2B10.SB10.M
dsf
81,92000
000
000
+ S B10.D2
B10.M
d
f
40,960
0
10,240
0
0PreS2B10.S s 1,280 10,240 0
0
PreS1 +PreS2+ S
B10.D2B10.SB10.M
dsf
81,9205,12010,240
5,12010,2401,280
6401,280
10,240
Milich et al. J. Immunol. 1986;137:315
![Page 26: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/26.jpg)
HBV envelope proteins and S-L*
1 126 175 400
preS1 preS2 HBsAg
12 52
133-145
175 400
S-L*
![Page 27: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/27.jpg)
Antibody response to HBsAg following administration of three additional
doses of Engerix-B or S-L* in poor responders
Month
0 1 2 3
Seroprotection rate (%)Engerix-B (n=18)S-L* (n=14)
00
8357
8971
8993
Geometric mean titer (mIU/ml)Engerix-B (n=18)S-L* (n=14)
3.43.7
24126
38565
540198
Leroux-Roels et al. Vaccine 1997;15:1732-6
![Page 28: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/28.jpg)
Persistence of immunity
• Level of anti-HBs declines after vaccination
• How long does protection last ?• Is booster immunization needed ?
• Very few breakthrough infections occur• Vaccination induces immune memory
![Page 29: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/29.jpg)
Persistence of anti-HBs Combined hepatitis A/B vaccine versus Engerix-B
(schedule : 0-1-6 months)
1
10
100
1000
10000
-6 0 6 12 18 24 30 36 42 48 54 60 66
TIMING (in months)
GM
Ts
in
mIU
/ml
(lo
g s
ca
le)
Twinrix (B)Engerix-B
![Page 30: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/30.jpg)
Persistence of immunity
• Levels of anti-HAV and anti-HBs decline after vaccination
• How long does protection last ?• Is booster immunization needed ?
• Very few breakthrough infections occur• Vaccination induces immune memory
![Page 31: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/31.jpg)
Demonstration of CMI towards HAVMethods - Subjects (1)
• Subjects enrolled in this project were recruited from 2 follow-up studies of long-term antibody persistence after the administration of 2 doses of 1440 EU HAV vaccine– study HAV-112 : 0-12 month scheme– study HAV-123 : 0-6 month scheme
• anti-HAV titers were measured on months 24, 36, 48, 60 and 72
![Page 32: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/32.jpg)
Demonstration of CMI towards HAVMethods - Subjects (2)
• Based on the anti-HAV titers measured on month 60, two groups were defined
Group H anti-HAV > 200 U/L n=20
Group L anti-HAV < 200 U/L n=16
• At month 72 blood was drawn to measure antibodies and HAV-specific cell mediated immune responses
![Page 33: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/33.jpg)
High Titered Group HAV CMI response TT
Study # Subject # anti-HAV Proliferation IFN- IL-5 Proliferation(U/L) (SI) (pg/ml) (pg/ml) (SI)
10 300 3,1 63 5 14,658 1325 1,5 10 5 27,465 3316 3,1 1010 5 13,2
101 1291 7,9 1050 20,5 20,9HAV-112 107 243 1,4 10 5 1,9
128 339 5,7 1400 214,8 8,6135 3731 24,2 964 5 120,3149 2020 97,5 1400 49,8 117,1176 4738 9,2 94 5 60,8184 290 2,2 70 5 81,48 804 15,6 534 17,2 22,516 287 10,2 197 5 119,818 407 29,5 492 5 112,319 666 8 1400 55 61,1
HAV-123 21 2387 2,5 51 5 12,224 442 2,5 45 5 26,133 2541 47,2 1400 5 29,750 377 5,7 65 5 28,955 1459 14,8 1388 15,8 22,657 902 8,6 284 5 12,2
RESULTS
15/20 18/20
![Page 34: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/34.jpg)
Low Titered Group HAV CMI response TT
Study # Subject # anti-HAV Proliferation IFN- IL-5 Proliferation(U/L) (SI) (pg/ml) (pg/ml) (SI)
13 102 1,1 10 5 30,444 197 12 349 5 12,247 10 1,4 10 5 20,551 55 3,6 377 14,6 11,5
HAV-112 56 193 2,6 399 5 26,462 185 1,3 10 5 11,377 108 3 606 5 39,786 85 1,1 10 5 66,792 156 1,4 10 5 63,1
103 186 1,4 10 5 1,69 52 1,1 10 5 8,615 90 3,5 62 5 39,8
HAV-123 32 106 2 10 5 14,136 127 1,7 10 5 12,859 96 1,5 109 5 10,164 138 1,8 10 5 7,6
RESULTS
4/16 6/16
![Page 35: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/35.jpg)
Center for Vaccinology
Agnes VandeputteAli FarhoudiAndrea VerwulgenAnnick WillemsArsène-Hélène BatensCao TinghuaFrédéric ClementFreya Van HoutteIsabelle DesombereLieve Van CrombruggeLieven VerhoyePeter VanlandschootPhilip MeulemanSophia SteyaertSybil CouventYvonne Gijbels
![Page 36: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/36.jpg)
Recommendations of the European Consensus Group in Hepatitis B Immunity
• No boosters for immunocompetent individuals who have responded to a primary course
• in certain risk groups boosters may be used to provide reassurance of protective immunity
• for immunocompromised patients regular testing for anti-HBs and booster injections when titer falls below 10mIU/ml are recommended
• non-responders to a primary course should continue to be studied
• long-term monitoring should continue
Lancet 2000;355:561-5
![Page 37: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/37.jpg)
ResultsBinding Reactivity of Human anti-HBsAg mAb with Wild-type and Mutant HBsAg
0
200
400
600
800
1000
1200
1400
1600
wt ayw
3
R122K
A128V
Q129R
G130N
M13
3T
Y134F
S136T
K141W
D144H
G145A
G145R
T148A
S154E
K160R
Wild-type and mutant HBsAg
A45
0 n
m
Cut-off320
![Page 38: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/38.jpg)
HBsAg vaccine escape variants
• Point mutations in the second ‘a’ loop, notably at amino acids 144 and 145, alter antigenicity dramatically
• these mutations confer escape characteristics to HBV under pressure mediated by rHBsAg-induced antibodies
![Page 39: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/39.jpg)
Will escape variants ever become important ?
Model simulation representing the worse case scenario with a highly infectious variant and a non-cross-reactive vaccine
Wilson et al. J.Viral Hepat. 1998;5(suppl2):25-30
![Page 40: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/40.jpg)
T and B cell responses during acute and chronic HBV infections
HBV antigens Al/TH/CTL Acuteinfection
Chronicinfection
HBsAg/pre-S AbTH
CTL
+++++ (PBL)
+/-+/-+ (liver)
HBc/HBeAg AbTH
CTL
+++++++ (PBL)
+++++ (liver)
Polymerase AbCTL
++++ (PBL)
+++ (liver)
![Page 41: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/41.jpg)
Vaccination induces memory
In vivo antibody production In vitro lymphoproliferation
• in vivo humoral and in vitro anti-HBs responses are closely correlated• booster responses reveal the immune memory
Leroux-Roels et al. Vaccine 1994;12:812-8
![Page 42: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/42.jpg)
B cell
Hepatocyte
CD8+
CTL CD4+Th cell
YY
Y
YY
APCNK
NKTcells
The principal actors
![Page 43: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/43.jpg)
Strategies to overcome nonresponsiveness
• Add preS-epitopes to HBsAg vaccine
• Change vaccine carrier– DNA vaccines– HBcAg as carrier
• More immunogenic adjuvants
• Give additional vaccine doses
![Page 44: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/44.jpg)
Engerix-B
S-L*
Evolution of anti-HBs in response to three additional vaccine doses given to 18 subjects with a poor response to 4 doses of HB vaccine
Leroux-Roels et al. Vaccine 1997;15:1732-6
2
2
7
4
4
1
![Page 45: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/45.jpg)
Severe combined immunodeficient
mousePrkdcscid/Prkdcscid
(SCID)– autosomal recessive
mutation in mice– severe deficiency in mature
lymphocytes– virtual absence of lypmhoid
cells in the thymus, spleen, lymph nodes and gut
– no Ab production, no DTH response, no graft rejection
– innate immune system is intact
![Page 46: Hepatitis B vaccination: an alternative (re)view Geert Leroux-Roels Center for Vaccinology Ghent University and Hospital](https://reader035.vdocuments.mx/reader035/viewer/2022062421/56649e015503460f94aeaeaa/html5/thumbnails/46.jpg)
In vivo exposure to a recall antigen activates Ag-specificB cell clones
Anti-HBsTiter inIU/ L
Donor HuPBL-SCID
HuPBL-SCID +HBsAg
Plasma 6981 180 2502
Culturesupe
0 26 320
Depraetere et al. J Immunol 2001;166:2929